On Tuesday, Shares of Marvell Technology Group Ltd. (NASDAQ:MRVL), gained 0.43% to $9.29. The stock attained the volume of 4.33 million shares.
Marvell (MRVL) — a worldwide leader in providing complete silicon solutions from storage to Internet of Things (IoT), cloud infrastructure, digital entertainment, in-home content delivery and Kinoma® software enabling the “Smart Life and Smart Lifestyle”— declared that the Company has been named an “Outstanding Large Company of the Year” by the IEEE’s Region 6 Director. This award, handed out annually, honored Marvell as a top company in 2015 located within IEEE’s Region 6, the Western United States, recognizing the Company’s contributions and commitment to support technologies that have advanced the engineering community and made a difference to the world at large. The awards were presented at an evening event at the IEEE Global Humanitarian Technology Conference (GHTC) 2015 in Seattle on October 10th.
From its roots as a Silicon Valley start-up founded in 1995 to now one of the world’s leading fabless semiconductor companies, Marvell has continually raised the technology bar, and its innovative system-on-chip (SoC) and software platforms have been adopted by tier one service providers and top OEMs around the globe. Building on the Company’s rich history of leadership and contribution in advancing semiconductor technology, Marvell has set its sights on the future of integrated circuit (IC) design. Marvell’s recent MOdular CHIp (MoChi™) interconnect and Final-Level Cache (FLC) memory innovation provides the foundation for a noteworthy paradigm shift that is designed to revolutionize IC design by lowering the cost and complexity of next-generation chips and systems.
Marvell Technology Group Ltd. designs, develops, and markets analog, mixed-signal, digital signal processing, and embedded and standalone integrated circuits.
At the end of Tuesday’s trade, Shares of Emerson Electric Co. (NYSE:EMR), declined -0.98% to $46.49.
It traded in a range of $46.38 and $47.14, exchanging hands with 4.13 million shares.
Sasol, an international energy and chemical company, has selected Emerson Process Administration to assist automate its $8.9 billion petrochemical complex in Lake Charles, La., designed to take advantage of abundant, low cost natural gas. The automation project is one of the largest in history awarded to Emerson.
When accomplished sometime in 2018, the massive petrochemical complex will more than triple Sasol’s chemical production capacity in the United States. The complex comprises an ethane cracker that will produce 1.5 million tons of ethylene annually, in addition to six chemical manufacturing plants designed to convert the ethylene into a diverse range of chemicals. Ethylene is a key ingredient in the production of plastics, detergents, anti-freeze, and other petrochemical products.
A business of Emerson (EMR), Emerson Process Administration implemented a detailed engineering and project execution plan designed to mitigate project risks, lower costs and reduce time to completion, all part of the company’s planned Project Certainty initiative.
Emerson Electric Co. provides technology and engineering solutions to industrial, commercial, and consumer markets worldwide. It operates through five segments: Process Administration, Industrial Automation, Network Power, Climate Technologies, and Commercial & Residential Solutions.
Finally, Shares of RXi Pharmaceuticals Corp (NASDAQ:RXII), ended its last trade with 11.80% gain, and closed at $0.597.
RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, declared that Dr. Robert Galiano, one of the Company’s Principal Investigators for the RXI-109 clinical program, will present during The Plastic Surgery Foundation (PSF) Industry Summit. The Summit will take place on Sunday, October 18, 2015 from 3:30-4:45 p.m. EDT in Boston, Massachusetts. Dr. Galiano will present an overview of the Company’s dermal clinical program with RXI-109. The presentation will be accessible on the “Investors” section of the Company’s website, www.rxipharma.com.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
